Earnings summaries and quarterly performance for DENTSPLY SIRONA.
Executive leadership at DENTSPLY SIRONA.
Daniel T. Scavilla
Detailed
President and Chief Executive Officer
CEO
AL
Andrea L. Frohning
Senior Vice President, Chief Human Resources Officer
KC
Kevin Czerney
Vice President, Chief Accounting Officer
RC
Richard C. Rosenzweig
Executive Vice President, Corporate Development, General Counsel and Secretary
R(
Robert (Tony) A. Johnson
Senior Vice President, Chief Supply Chain Officer
Board of directors at DENTSPLY SIRONA.
BD
Betsy D. Holden
Detailed
Director
BT
Brian T. Gladden
Detailed
Director
CR
Clyde R. Hosein
Detailed
Director
GT
Gregory T. Lucier
Detailed
Non-Executive Chairman of the Board
JS
Janet S. Vergis
Detailed
Director
JJ
Jonathan J. Mazelsky
Detailed
Director
LF
Leslie F. Varon
Detailed
Director
MJ
Michael J. Barber
Detailed
Director
WA
Willie A. Deese
Detailed
Director
Research analysts who have asked questions during DENTSPLY SIRONA earnings calls.
BV
Brandon Vazquez
William Blair & Company, L.L.C.
6 questions for XRAY
Also covers: ALGN, CBLL, CVRX +17 more
DS
David Saxon
Needham & Company
6 questions for XRAY
Also covers: ALC, ALGN, ATEC +11 more
Elizabeth Anderson
Evercore ISI
5 questions for XRAY
Also covers: AGL, ALGN, CAH +24 more
Jonathan Block
Stifel Financial Corp.
5 questions for XRAY
Also covers: ALGN, COO, CUTR +11 more
Allen Lutz
Bank of America
4 questions for XRAY
Also covers: ACCD, CAH, COR +15 more
EW
Erin Wright
Morgan Stanley
4 questions for XRAY
Also covers: ALGN, BTSG, CAH +19 more
Jeffrey Johnson
Robert W. Baird & Co. Inc.
4 questions for XRAY
Also covers: ALC, ALGN, BBNX +11 more
Michael Cherny
Leerink Partners
4 questions for XRAY
Also covers: ACCD, ACH, AKBA +23 more
Jason Bednar
Piper Sandler Companies
3 questions for XRAY
Also covers: ALGN, COO, EDAP +17 more
MS
Michael Sarcone
Jefferies
3 questions for XRAY
Also covers: ALC, ALGN, AXGN +12 more
VC
Vik Chopra
Wells Fargo & Company
3 questions for XRAY
Also covers: ALGN, ATEC, CNMD +8 more
Daniel Clark
Leerink Partners
2 questions for XRAY
Also covers: CERT, ELAN, IDXX +6 more
DF
Dylan Finley
B. Riley Securities
2 questions for XRAY
Also covers: ALGN, SOLV, ZIMV
GS
Glen Santangelo
Jefferies
2 questions for XRAY
Also covers: ALGN, ANIP, BHC +16 more
Jeff Johnson
Robert W. Baird & Co.
2 questions for XRAY
Also covers: ALC, ALGN, BBNX +8 more
Kevin Caliendo
UBS
2 questions for XRAY
Also covers: ACH, AHCO, ALGN +18 more
LL
Lily Lozada
JPMorgan Chase & Co.
2 questions for XRAY
Also covers: ATRC, CVRX
MP
Michael Petusky
Barrington Research
2 questions for XRAY
Also covers: ANIK, HAE, HSIC +9 more
Steven Valiquette
Mizuho
2 questions for XRAY
Also covers: ALGN, CAH, COR +12 more
JB
Jon Block
Stifel, Nicolaus & Company, Incorporated
1 question for XRAY
Also covers: ALGN, BBNX, COO +8 more
Simran
Wells Fargo & Company
1 question for XRAY
Also covers: DXCM, PODD
Recent press releases and 8-K filings for XRAY.
Dentsply Sirona Reports Q4 and Full Year 2025 Results, Initiates Return-to-Growth Plan, and Updates Capital Allocation
XRAY
Earnings
Guidance Update
Dividends
- Dentsply Sirona reported Q4 2025 revenue of $961 million, a 6.2% reported increase, and adjusted EPS of $0.27. For the full year 2025, sales were $3.68 billion and adjusted EPS was $1.60.
- The company introduced a 24-month Return-to-Growth action plan and announced a restructuring program expected to unlock approximately $120 million annually for reinvestment.
- As part of a strategic review, Dentsply Sirona has eliminated its dividends, reallocating these funds towards debt retirement and share repurchases.
- For 2026, net sales are projected to be between $3.5 billion and $3.6 billion, reflecting -3% to -1% operational growth, and adjusted EPS is expected to be in the range of $1.40-$1.50.
1 day ago
Dentsply Sirona Reports Q4 and Full Year 2025 Results, Outlines 2026 Guidance and Strategic Initiatives
XRAY
Earnings
Guidance Update
Dividends
- Dentsply Sirona reported Q4 2025 revenue of $961 million, a 6.2% increase (2.5% constant currency), and adjusted EPS of $0.27. For the full year 2025, sales were $3.68 billion, a 3% decline (4.3% constant currency), with adjusted EPS of $1.60.
- The company initiated a restructuring program expected to unlock approximately $120 million annually and eliminated its dividend to reallocate funds towards debt retirement and share repurchases.
- For 2026, Dentsply Sirona expects net sales between $3.5 billion and $3.6 billion, reflecting -3% to -1% operational growth, and adjusted EPS in the range of $1.40 to $1.50.
- Strategic initiatives include increasing R&D investment by double digits and clinical education by 50%, reorganizing commercial teams, and expanding dealer agreements as part of its "Return to Growth" action plan.
1 day ago
DENTSPLY SIRONA Reports Q4 and Full Year 2025 Results and Provides 2026 Outlook
XRAY
Earnings
Guidance Update
Share Buyback
- DENTSPLY SIRONA reported Q4 2025 net sales of $961 million, a 6.2% increase year-over-year, and adjusted EPS of $0.27, up 4.9% year-over-year.
- For the full year 2025, the company achieved an adjusted EBITDA margin of 18.1% and adjusted EPS of $1.60.
- The company initiated a new capital allocation strategy, which includes the elimination of the dividend and reallocating funds towards debt paydown and share buybacks.
- DENTSPLY SIRONA announced a restructuring plan to redirect $120 million annually into its Return-to-Growth Action Plan and appointed three new members to its Board of Directors.
- For 2026, the company expects net sales between $3.5 billion and $3.6 billion, and adjusted EPS in the range of $1.40 to $1.50.
1 day ago
Dentsply Sirona Reports Q4 and Full-Year 2025 Results, Outlines "Return to Growth" Plan and 2026 Guidance
XRAY
Earnings
Dividends
Guidance Update
- Dentsply Sirona reported Q4 2025 revenue of $961 million and adjusted EPS of $0.27, with full-year 2025 sales reaching $3.68 billion and adjusted EPS of $1.60.
- The company announced the elimination of its dividend to reallocate funds towards debt retirement and share repurchases, aiming to maintain investment-grade credit metrics.
- A restructuring program is expected to unlock approximately $120 million annually across the P&L, with $55 million-$65 million in nonrecurring charges anticipated in 2026 and 2027.
- For 2026, Dentsply Sirona expects net sales in the range of $3.5 billion-$3.6 billion (reflecting -3% to -1% operational growth) and adjusted EPS between $1.40-$1.50, reflecting accelerated investments in innovation, clinical education, and commercial initiatives.
- The company is implementing a "Return to Growth" action plan, focusing on customer-centricity, reigniting sustainable growth, empowering performance, scaling the organization, and strengthening financial health, including double-digit increases in R&D investment for 2026.
1 day ago
Dentsply Sirona Outlines Return-to-Growth Plan and Strategic Priorities
XRAY
New Projects/Investments
Revenue Acceleration/Inflection
Management Change
- Dentsply Sirona's CEO, Daniel Scavilla, detailed a return-to-growth plan aiming to increase R&D investment from 4% to 6% of sales and unlock $100 million from the P&L to fund commercial growth and innovation.
- The plan prioritizes a U.S. business turnaround through commercial restructuring, verticalized sales teams, and expanded dealer networks, with expectations for sequential improvements in the second half of 2026 and positive sales growth in Q4 2026 for the company broadly.
- Strategic investments will focus on the DS Core platform and areas like Implantology and Orthodontics, alongside doubling clinical education investment to $40 million annually.
- The company plans to improve free cash flow by reducing inventory by 20% and expects a 26-28% tax rate in 2026, with a long-term target of 25% or less.
- Dentsply Sirona retained its Wellspect business due to an undervalued bid and its contribution of 40% of annual cash flow, with plans for independent operation.
Jan 13, 2026, 11:00 PM
Dentsply Sirona Outlines Return-to-Growth Plan and 2026 Outlook at J.P. Morgan Healthcare Conference
XRAY
New Projects/Investments
Revenue Acceleration/Inflection
Management Change
- CEO Daniel Scavilla, who joined five months ago, has initiated a comprehensive return-to-growth plan for Dentsply Sirona, focusing on customer-centricity, reigniting sustainable growth, empowering performance, scaling the organization, and delivering financial strength.
- Key financial and operational initiatives include increasing R&D investment from its current 4% to 6% of P&L (or 7% cash basis) over the next 24 months, unlocking $100 million from the P&L to fund growth, and improving free cash flow by reducing inventory by 20%.
- The company expects sequential improvements in the second half of 2026, with a target of positive sales growth in Q4 2026 and market growth in 2027, primarily driven by the turnaround of the US business.
- Recent actions to support this plan include signing Benco as a new capital distributor, verticalizing the US commercial teams, and appointing Mark Bezjak to lead the US organization.
- The Wellspect business, which contributes 40% of annual cash flow, was retained after a strategic review and is being managed independently with an independent board being established.
Jan 13, 2026, 11:00 PM
Dentsply Sirona Outlines Return-to-Growth Plan and Strategic Initiatives
XRAY
New Projects/Investments
Revenue Acceleration/Inflection
Management Change
- CEO Dan Scavilla, who joined five months ago, outlined a five-pillar return-to-growth plan for Dentsply Sirona, addressing past underperformance and targeting market growth by 2027.
- The plan includes doubling clinical education investment to $40 million annually and accelerating R&D spending from 4% to a target of 6% of sales on the P&L (7% cash basis) over the next 24 months.
- Dentsply Sirona aims to unlock $100 million from the P&L to fund commercial growth and innovation, with a focus on turning around the U.S. business and expecting sequential improvements in the second half of 2026 and positive sales growth in Q4 2026.
- Recent strategic actions include signing Benco as a new capital distributor, verticalizing U.S. commercial teams, and appointing Don Zurbay (former CEO of Patterson) to the board.
- The company retained its Wellspect business, which contributes 40% of annual cash flow, and is targeting a 26-28% tax rate in 2026.
Jan 13, 2026, 11:00 PM
Dentsply Sirona Presents at J.P. Morgan Healthcare Conference
XRAY
New Projects/Investments
CFO Change
Board Change
- Dentsply Sirona presented at the J.P. Morgan Healthcare Conference on January 13, 2026, detailing its Return-to-Growth Action Plan, which was initiated in November 2025.
- The company operates in an attractive $33 billion market with a 3-4% Compound Annual Growth Rate (CAGR) and reported FY2024 sales by segment as 38% Essential Dental Solutions, 28% Connected Technology Solutions, 26% Orthodontic and Implant Solutions, and 8% Wellspect Healthcare.
- The Return-to-Growth Action Plan aims to unlock +$100 million in P&L improvement and includes key accomplishments since Q3 2025 such as a distributor expansion agreement with Benco, the hiring of interim CFO Michael Pomeroy, and the appointment of Don Zurbay to the Board of Directors.
Jan 13, 2026, 11:00 PM
DENTSPLY SIRONA Inc. Amends Credit and Note Purchase Agreements
XRAY
Debt Issuance
Accounting Changes
- DENTSPLY SIRONA Inc. amended its revolving credit facility and note purchase agreements on December 24, 2025, to revise financial covenants and introduce new restrictions.
- The company established new Total Leverage Ratio covenants, which will not exceed 4.25 to 1.00 for the fiscal quarters ending December 31, 2025, through June 30, 2026, and will progressively tighten to 3.50 to 1.00 by September 30, 2027, and subsequent quarters.
- New Senior Leverage Ratio covenants were also set, starting at 3.25 to 1.00 for the fiscal quarters ending December 31, 2025, through June 30, 2026, and reducing to 2.50 to 1.00 for September 30, 2027, and each quarter thereafter.
- A new covenant was added that prohibits Restricted Payments, with specified exceptions.
- The definition of EBITDA was modified to include specific addbacks for charges and expenses related to efficiency initiatives, with an aggregate limit of $75,000,000 for the period from December 31, 2025, through December 31, 2026, and an overall aggregate limit of $200,000,000.
Dec 31, 2025, 9:25 PM
Dentsply Sirona Reports Q3 2025 Results, Announces CFO Departure, and Outlines Growth Plan
XRAY
Earnings
CFO Change
New Projects/Investments
- Dentsply Sirona reported Q3 2025 global sales of $904 million, a 5% decrease as reported, or negative 8% on a constant currency basis. Non-GAAP earnings per share was $0.37, down $0.13 versus the prior year, with approximately half the decline attributed to higher non-GAAP tax rates.
- The company recorded a $263 million non-cash after-tax charge related to the impairment of goodwill and intangible assets.
- Matt Garth, Chief Financial Officer, departed the company, with a transition plan in place to ensure continuity.
- CEO Dan Scavilla outlined a "return-to-growth action plan" for the next 24 months, focusing on enhancing customer experience, reigniting the U.S. business through a multi-channel approach and dealer re-engagement, and increasing investments in sales teams and clinical education.
Nov 6, 2025, 1:30 PM
Quarterly earnings call transcripts for DENTSPLY SIRONA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more